Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2019 Jun 29

PMID 31250582

Citations 24

Authors

Hyesung Lee

Ha Lim Jeon

Sang Jun Park

Ju Young Shin

Affiliations

Soon will be listed here.

Abstract

Purpose: Statins, metformin, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) have been suggested for treating age-related macular degeneration (AMD) due to their pleiotropic effects. Therefore, we investigated whether these drugs prevent AMD.

Materials And Methods: We conducted a nested case-control study using the Korean National Health Insurance Service database. Using risk-set sampling of age, sex, cohort entry date, and follow-up duration, we identified incident patients with AMD and 10 matching controls in cohorts with diabetes mellitus or cardiovascular diseases. Exposure was assessed within one year before the index date using patient prescription records. We conducted conditional logistic regression to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the association between cardiovascular medications and AMD.

Results: Our study included 2330 cases and 23278 controls from a cohort of 231274 patients. The ORs (95% CI) for AMD occurrence in users prescribed with statins, metformin, ACE inhibitors, and ARBs were 1.12 (0.94-1.32), 1.15 (0.91-1.45), 0.90 (0.61-1.34), and 1.21 (1.05-1.39), respectively. A duration-response was not observed.

Conclusion: Statins, metformin, ACE inhibitors, and ARBs did not inhibit AMD in elderly patients. The absence of a duration-response supports the lack of a causal relationship.

Citing Articles

Different Therapeutic Approaches for Dry and Wet AMD.

Marchesi N, Capierri M, Pascale A, Barbieri A Int J Mol Sci. 2024; 25(23).

PMID: 39684764 PMC: 11641571. DOI: 10.3390/ijms252313053.

Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration.

Xiao J, Luo W, Mani A, Barba H, Solanki A, Droho S Int J Mol Sci. 2024; 25(21).

PMID: 39518910 PMC: 11545389. DOI: 10.3390/ijms252111357.

Unveiling Statins and Genetics in Age-Related Macular Degeneration: The Coimbra Eye Study-Report 9.

Barreto P, Farinha C, Coimbra R, Cachulo M, Melo J, Lechanteur Y Invest Ophthalmol Vis Sci. 2024; 65(6):38.

PMID: 38935028 PMC: 11216251. DOI: 10.1167/iovs.65.6.38.

METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial.

Shen L, Keenan J, Chahal N, Taha A, Saroya J, Ma C Ophthalmol Sci. 2024; 4(3):100440.

PMID: 38284098 PMC: 10810745. DOI: 10.1016/j.xops.2023.100440.

The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration.

Garcia-Quintanilla L, Almuina-Varela P, Rodriguez-Cid M, Gil-Martinez M, Abraldes M, Gomez-Ulla F Pharmaceutics. 2024; 16(1).

PMID: 38258115 PMC: 10818382. DOI: 10.3390/pharmaceutics16010105.

References

Sedgwick P . Case-control studies: advantages and disadvantages. BMJ. 2019; 348:f7707. DOI: 10.1136/bmj.f7707. View

Congdon N, Friedman D, Lietman T . Important causes of visual impairment in the world today. JAMA. 2003; 290(15):2057-60. DOI: 10.1001/jama.290.15.2057. View

van Leeuwen R, Tomany S, Wang J, Klein R, Mitchell P, Hofman A . Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology. 2004; 111(6):1169-75. DOI: 10.1016/j.ophtha.2003.10.024. View

McGwin Jr G, Xie A, Owsley C . The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology. 2005; 112(3):488-94. DOI: 10.1016/j.ophtha.2004.10.027. View

Kortekaas K, Meijer C, Hinnen J, Dalman R, Xu B, Hamming J . ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm. PLoS One. 2014; 9(12):e111952. PMC: 4256371. DOI: 10.1371/journal.pone.0111952. View

Shin J, Choi N, Jung S, Kim Y, Seong J, Park B . Overlapping medication associated with healthcare switching among Korean elderly diabetic patients. J Korean Med Sci. 2011; 26(11):1461-8. PMC: 3207049. DOI: 10.3346/jkms.2011.26.11.1461. View

Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B . Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014; 3(6):e001202. PMC: 4338706. DOI: 10.1161/JAHA.114.001202. View

Oesterle A, Laufs U, Liao J . Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017; 120(1):229-243. PMC: 5467317. DOI: 10.1161/CIRCRESAHA.116.308537. View

Park S, Kwon K, Choi N, Park K, Woo S . Prevalence and Incidence of Exudative Age-Related Macular Degeneration in South Korea: A Nationwide Population-Based Study. Ophthalmology. 2015; 122(10):2063-70.e1. DOI: 10.1016/j.ophtha.2015.06.018. View

10.

van Leeuwen R, Boekhoorn S, Vingerling J, Witteman J, Klaver C, Hofman A . Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA. 2005; 294(24):3101-7. DOI: 10.1001/jama.294.24.3101. View

11.

Hall N, Gale C, Syddall H, Phillips D, Martyn C . Risk of macular degeneration in users of statins: cross sectional study. BMJ. 2001; 323(7309):375-6. PMC: 37398. DOI: 10.1136/bmj.323.7309.375. View

12.

Smith B, Joseph D, Grand M . Treatment of neovascular age-related macular degeneration: past, present and future directions. Curr Opin Ophthalmol. 2007; 18(3):240-4. DOI: 10.1097/ICU.0b013e32810c8e05. View

13.

Snow K, Seddon J . Do age-related macular degeneration and cardiovascular disease share common antecedents?. Ophthalmic Epidemiol. 1999; 6(2):125-43. DOI: 10.1076/opep.6.2.125.1558. View

14.

Klein R, Klein B, Tomany S, Danforth L, Cruickshanks K . Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol. 2003; 121(8):1151-5. DOI: 10.1001/archopht.121.8.1151. View

15.

Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher A . A case control study of age related macular degeneration and use of statins. Br J Ophthalmol. 2005; 89(9):1171-5. PMC: 1772815. DOI: 10.1136/bjo.2004.064477. View

16.

McCarty C, Mukesh B, Guymer R, Baird P, Taylor H . Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust. 2001; 175(6):340. DOI: 10.5694/j.1326-5377.2001.tb143604.x. View

17.

Colijn J, Buitendijk G, Prokofyeva E, Alves D, Cachulo M, Khawaja A . Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017; 124(12):1753-1763. PMC: 5755466. DOI: 10.1016/j.ophtha.2017.05.035. View

18.

Etminan M, Brophy J, Maberley D . Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: nested case-control study. Curr Drug Saf. 2008; 3(1):24-6. DOI: 10.2174/157488608783333952. View

19.

Thomas A, Redd T, Hwang T . EFFECT OF SYSTEMIC BETA-BLOCKERS, ACE INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS ON DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION. Retina. 2015; 35(10):1964-8. DOI: 10.1097/IAE.0000000000000603. View

20.

Chrysant S, Chrysant G . The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich). 2006; 8(4):261-8. PMC: 8109722. DOI: 10.1111/j.1524-6175.2005.05264.x. View